ELEVIDYS is the first FDA-approved gene therapy for Duchenne and the first gene therapy to address the root cause of the muscle-wasting disease. Sarepta developed a way to replace the broken dystrophin gene with a working version that protects muscles, thereby slowing disease progression. It offers hope to those living with the fatal disease.